Last reviewed · How we verify
RO5045337
At a glance
| Generic name | RO5045337 |
|---|---|
| Also known as | MDM2 ANTAGONIST |
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies (PHASE1)
- A Study of RO5045337 [RG7112] in Patients With Advanced Solid Tumors (PHASE1)
- A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia (PHASE1)
- A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms. (PHASE1)
- A Study of RO5045337 in Patients With Solid Tumors (PHASE1)
- A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma (PHASE1)
- A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RO5045337 CI brief — competitive landscape report
- RO5045337 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI